Skip to main content
Erschienen in: Wiener klinische Wochenschrift 17-18/2013

01.09.2013 | case report

Peginterferon alfa related psoriasis in a patient with acute hepatitis C and review of the literature

verfasst von: Muhammed Sait Dag, MD, Specialist, Zeynel Abidin Öztürk, MD, Specialist, Nimet Yılmaz, MD, Specialist, Hakan Çam, MD, Specialist, Prof. Abdurrahman Kadayıfçı

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 17-18/2013

Einloggen, um Zugang zu erhalten

Summary

The Interferon (IFN) which is the standard treatment for Hepatitis C, may cause a lot of side effects including dermatological anomalies. This paper presents a psoriasis case which occurred in relation with the treatment of acute hepatitis C (AHC) with peginterferon alfa (peg-IFN-α). A 60-year-old male patient came to the hospital with symptoms of high liver enzymes. The patient with history of a recent operation showed anti-HCV (+), HCVRNA 3.5 million IU/mL and HCV genotype 1b in the tests. Without any other etiological factors found in the patient, we started a treatment of peg-IFNα-2b with the diagnosis of AHC. After 3 weeks, psoriatic plaques were observed in various parts of the body. Antiviral treatment of the patient was concluded within 6 months. His psoriasis treatment initially commenced with local agents followed by phototherapy. Permanent viral response was seen in the patient and his lesions recovered rapidly after the antipsoriatic and antiviral treatment. Psoriasis and other autoimmune diseases should be considered even though they are encountered rarely,and the patients should be informed of the possible risks before planning treatment with peg-IFN-α.
Literatur
1.
Zurück zum Zitat Caruntu FA, Benea L. Acute hepatitis C virus infection: Diagnosis, pathogenesis, treatment. J Gastrointestin Liver Dis. 2006;15(3):249–56.PubMed Caruntu FA, Benea L. Acute hepatitis C virus infection: Diagnosis, pathogenesis, treatment. J Gastrointestin Liver Dis. 2006;15(3):249–56.PubMed
2.
Zurück zum Zitat Dienstag JL, McHutchison JG. American Gastroenterological Association. Technical review on the management of hepatitis C. Gastroenterology. 2006;130(1):231–64.PubMedCrossRef Dienstag JL, McHutchison JG. American Gastroenterological Association. Technical review on the management of hepatitis C. Gastroenterology. 2006;130(1):231–64.PubMedCrossRef
3.
Zurück zum Zitat Mistry N, Shapero J, Crawford RI. A review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin. Can J Gastroenterol. 2009;23(10):677–83.PubMed Mistry N, Shapero J, Crawford RI. A review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin. Can J Gastroenterol. 2009;23(10):677–83.PubMed
4.
Zurück zum Zitat Chong VH. Autoimmune thyroiditis and delayed onset psoriasis in association with combination therapy for chronic hepatitis C infection. Singapore Med J. 2011;52(2):20–2. Chong VH. Autoimmune thyroiditis and delayed onset psoriasis in association with combination therapy for chronic hepatitis C infection. Singapore Med J. 2011;52(2):20–2.
5.
Zurück zum Zitat Wu MC, Lee JY. Generalized flare of pustular psoriasis induced by PEGylated interferon-α2b therapy for chronic hepatitis C. Australas J Dermatol. 2012;53(4):69–72.CrossRef Wu MC, Lee JY. Generalized flare of pustular psoriasis induced by PEGylated interferon-α2b therapy for chronic hepatitis C. Australas J Dermatol. 2012;53(4):69–72.CrossRef
6.
Zurück zum Zitat Yurci A, Guven K, Torun E, et al. Pyoderma gangrenosum and exacerbation of psoriasis resulting from pegylated interferon alpha and ribavirin treatment of chronic hepatitis C. Eur J Gastroenterol Hepatol. 2007;19(9):811–5.PubMedCrossRef Yurci A, Guven K, Torun E, et al. Pyoderma gangrenosum and exacerbation of psoriasis resulting from pegylated interferon alpha and ribavirin treatment of chronic hepatitis C. Eur J Gastroenterol Hepatol. 2007;19(9):811–5.PubMedCrossRef
7.
Zurück zum Zitat Traub M, Marshall K. Psoriasis-pathophysiology, conventional, and alternative approaches to treatment. Altern Med Rev. 2007;12(4):319–30.PubMed Traub M, Marshall K. Psoriasis-pathophysiology, conventional, and alternative approaches to treatment. Altern Med Rev. 2007;12(4):319–30.PubMed
8.
Zurück zum Zitat Shiffman ML. Pegylated interferons: what role will they play in the treatment of chronic hepatitis C? Curr Gastroenterol Rep. 2001;3(1):30–7.PubMedCrossRef Shiffman ML. Pegylated interferons: what role will they play in the treatment of chronic hepatitis C? Curr Gastroenterol Rep. 2001;3(1):30–7.PubMedCrossRef
9.
Zurück zum Zitat Tekin NS, Ustundag Y, Tekin IO, Koca R, Altinyazar HC. Early administration of ultraviolet treatment is effective in pegylated interferon alpha-induced severe acute exacerbation of psoriasis: a case report and short review of the literature. Int J Clin Pract. 2010;64(1):101–3.PubMedCrossRef Tekin NS, Ustundag Y, Tekin IO, Koca R, Altinyazar HC. Early administration of ultraviolet treatment is effective in pegylated interferon alpha-induced severe acute exacerbation of psoriasis: a case report and short review of the literature. Int J Clin Pract. 2010;64(1):101–3.PubMedCrossRef
10.
Zurück zum Zitat Downs AM, Dunnill MG. Exacerbation of psoriasis by interferon-alpha therapy for hepatitis C. Clin Exp Dermatol. 2000;25(4):351–2.PubMedCrossRef Downs AM, Dunnill MG. Exacerbation of psoriasis by interferon-alpha therapy for hepatitis C. Clin Exp Dermatol. 2000;25(4):351–2.PubMedCrossRef
11.
Zurück zum Zitat Funk J, Langeland T, Schrumpf E, Hanssen LE. Psoriasis induced by interferon-a. Br J Dermatol. 1991;125(5):463–5.PubMedCrossRef Funk J, Langeland T, Schrumpf E, Hanssen LE. Psoriasis induced by interferon-a. Br J Dermatol. 1991;125(5):463–5.PubMedCrossRef
12.
Zurück zum Zitat Ketikoglou I, Karatapanis S, Elefsiniotis I, Kafiri G, Moulakakis A. Extensive psoriasis induced by pegylated interferon alpha-2b treatment for chronic hepatitis B. Eur J Dermatol. 2005;15(2):107–9.PubMed Ketikoglou I, Karatapanis S, Elefsiniotis I, Kafiri G, Moulakakis A. Extensive psoriasis induced by pegylated interferon alpha-2b treatment for chronic hepatitis B. Eur J Dermatol. 2005;15(2):107–9.PubMed
13.
Zurück zum Zitat Horev A, Halevy S. New-onset psoriasis following treatment with pegylated interferon-alpha 2b and ribavirin for chronic hepatitis C. Isr Med Assoc J. 2009;11(12):760–1.PubMed Horev A, Halevy S. New-onset psoriasis following treatment with pegylated interferon-alpha 2b and ribavirin for chronic hepatitis C. Isr Med Assoc J. 2009;11(12):760–1.PubMed
14.
Zurück zum Zitat Mederacke I, Witte T, Wedemeyer H, Meyer-Olson D. Successful clearance of hepatitis C virus with pegylated interferon α-2a and ribavirin in an etanercept-treated patient with psoriatic arthritis, hepatitis B virus coinfection and latent tuberculosis. Ann Rheum Dis. 2011;70(7):1343–4.PubMedCrossRef Mederacke I, Witte T, Wedemeyer H, Meyer-Olson D. Successful clearance of hepatitis C virus with pegylated interferon α-2a and ribavirin in an etanercept-treated patient with psoriatic arthritis, hepatitis B virus coinfection and latent tuberculosis. Ann Rheum Dis. 2011;70(7):1343–4.PubMedCrossRef
15.
Zurück zum Zitat Bartalesi F, Salomoni E, Cavallo A, Corti G, Pimpinelli N, Bartoloni A, et al. Chronic hepatitis C virus hepatitis and psoriasis: No longer a contraindication to interferon use in the era of biological agents? Scand J Infect Dis. 2013;45(4):320–3.PubMedCrossRef Bartalesi F, Salomoni E, Cavallo A, Corti G, Pimpinelli N, Bartoloni A, et al. Chronic hepatitis C virus hepatitis and psoriasis: No longer a contraindication to interferon use in the era of biological agents? Scand J Infect Dis. 2013;45(4):320–3.PubMedCrossRef
Metadaten
Titel
Peginterferon alfa related psoriasis in a patient with acute hepatitis C and review of the literature
verfasst von
Muhammed Sait Dag, MD, Specialist
Zeynel Abidin Öztürk, MD, Specialist
Nimet Yılmaz, MD, Specialist
Hakan Çam, MD, Specialist
Prof. Abdurrahman Kadayıfçı
Publikationsdatum
01.09.2013
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 17-18/2013
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-013-0408-1

Weitere Artikel der Ausgabe 17-18/2013

Wiener klinische Wochenschrift 17-18/2013 Zur Ausgabe

mitteilungen der gesellschaft

Mitteilungen der Gesellschaft